The EGFR tyrosine kinase inhibitors as second-line therapy for EGFR wild-type non-small-cell lung cancer: a real-world study in People’s Republic of China

INTRODUCTION: Clinical evidence comparing chemotherapy and tyrosine kinase inhibitors (TKIs) as second-line therapy for epidermal growth factor receptor (EGFR) wild-type non-small-cell lung cancer (NSCLC) are conflicting. METHODS: We retrospectively reviewed stage IV EGFR wild-type NSCLC patients wh...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Onco Targets Ther
Main Authors: Xu, Jianlin, Ding, Guozheng, Zhang, Xueyan, Jin, Bo, Lou, Yuqing, Zhang, Yanwei, Wang, Huiming, Wu, Dan, Han, Baohui
Formato: Artigo
Idioma:Inglês
Publicado em: Dove Medical Press 2016
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5079695/
https://ncbi.nlm.nih.gov/pubmed/27799795
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S119341
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados